Clinical Trials Logo

Clinical Trial Summary

This protocol is for a pragmatic randomised controlled clinical trial (RCT) with a manual spinal mobilisation (MSM) intervention for patients with axial spondyloarthritis (axSpA), embedded in a Trials within Cohort (TwiCs) design. This trial might appear as a standardised RCT but there is a secondary element - an observational cohort the trial is embedded in. Trial A is the first (of possibly several) embedded pragmatic RCTs involving physiotherapy interventions that may identify therapies that will help improve outcomes for patients with axSpA. The investigators are seeking to improve outcomes for these patients by comparing different physiotherapy interventions in subsequent trials with standard of care (SoC) physiotherapy. Trial A will compare routine care vs routine care plus MSM physiotherapy attempting to answer the primary research question if MSM on patients with axSpA improves spinal mobility. In order to recruit patients and obtain outcomes for Trial A (n=70), the investigators will first recruit up to 300 axSpA patients receiving care at the Royal National Hospital for Rheumatic Diseases (RNHRD) in Bath into a cohort and observe their standard of care outcomes. This will allow to answer the cohort's research question of "How does SoC physiotherapy in patients with axSpA reflect in data collected routinely on outcomes of the disease?" Patients will be asked to consent to provide routine observational data on their wellbeing, be approached to take part in future trials of interventions which aim to improve outcomes for patients with axSpA, and not be approached unless they are offered the physiotherapy trial intervention. This highly pragmatic method of providing information and seeking consent replicates the informed consent procedures in routine care clinical settings. This study is aimed to last three years, with individual trials of 40-70 participants, ranging between three to six months duration of therapy intervention in addition to routine care.


Clinical Trial Description

A single pragmatic randomised controlled clinical trial (RCT) (Trial A) which is embedded in a series of pragmatic trials within the Trials within Cohort (TwiCs) design of the PaxSpA study. This trial will compare manual spinal mobilisation (MSM) intervention for patients with axial spondyloarthritis (axSpA) to routine care alone.This trial might appear as a standardised RCT but there is a secondary element - an observational cohort the trial is embedded in. Trial A is the first (of possibly several) embedded pragmatic RCTs involving physiotherapy interventions that may identify therapies that will help improve outcomes for patients with axSpA. The cohort might seem as an unnecessary add-on to what could be conducted as a standalone standardised RCT, but it has a few important advantages. By having a cohort the investigators can observe routine care physiotherapy outcomes for a large cohort giving data from a large number of patients. That data can be used to compare to across a range of interventions, as each embedded trial will use the same outcome measures and therefore results are comparable across trials to give a broader view of the care of this chronic progressive condition - axial Spondyloarthritis. The other advantage for having for having the cohort is to be able to have a control group receiving standard of care without having disappointment bias for not being in the intervention arm, as physiotherapy interventions can be very difficult to blind participants. The investigators plan to establish an observational cohort of 300 patients with axial spondyloarthritis (axSpA) currently treated at the RUH NHS Trust in Bath and observe their outcomes over the duration of the study, as a cornerstone for our "Trials within cohort" (TwiCs) study PaxSpA. Cohort patients will be asked to consent to (i) provide observational data on their wellbeing (standard routine axSpA PROM), (ii) be approached to take part in future trials of interventions which aim to improve outcomes for patients axSpA, and (iii) not be approached unless they are offered an experimental (i.e. non routine) intervention. Post randomisation, only those randomly selected to an experimental (non-routine) intervention will informed about the experimental interventions and asked for their 'clinical' consent to receive these intervention (i.e. Trial A: manual mobilisation). This method is known as the Trials within Cohorts (TwiCs) method and is currently being used in over 70 studies worldwide, including many in the United Kingdom (UK) and Canada. This method of providing information and seeking consent replicates the informed consent procedures in routine care and has several benefits. Firstly, it avoids unnecessary expectation and disappointment regarding the experimental interventions. Secondly, clinicians do not have to spend time explaining interventions to patients who will not be offered the intervention post randomisation. Thirdly, it enables fast and efficient recruitment to both trials. The investigators will then conduct the first of possibly several embedded pragmatic randomised controlled trials of adjunctive physiotherapy for patients with axSpA: Trial A will compare routine care vs routine care plus manual spinal mobilisation physiotherapy. The hypothesis for trial A assumes manual spinal mobilisation will improve function, decrease pain and decrease disease activity, but primarily increase spinal mobility, as shown in previous trials to be the case when specific parts of the spine received manual mobilisation. The study design and methodology has been chosen because of its highly pragmatic character in a clinical setting of a chronic condition. Physiotherapy in axSpA consists of a variety of treatment options to research and outcomes for each intervention can be compared to the routinely taken outcome measures across the cohort to identify and compare benefits/challenges of different interventions. The TwiCs design has been shown to be particularly suitable for chronic conditions, where different treatments are provided to inform clinical practice, and therefore the investigators identified this design to be best suited to meet the aims and objectives our study (also see second paragraph above). The justification for including control arms to a trial: The control arm is important for comparison of outcomes and to increase the validity of our study. The control arm will receive standard of care as usual (as will the intervention group), without the additional intervention, therefore the difference in results between the groups will indicate the effect of the trial intervention, enabling to inform clinical practice. Additionally, it is very challenging to blind participants and researcher to physiotherapy interventions, so randomisation with a control group gives our study a sound methodology. Randomisation will be achieved my random computer allocation in a staged (phased) randomisation process. Initially all cohort participants will get screened for eligibility for trial A and if successful, included into the eligible trial cohort. For trial A the investigators aim to recruit 12 participants per stage/batch into the manual mobilisation trial for six batches (up to 70 participants). For each batch, six participants will get randomly selected from the eligible trial cohort to be offered to receive the intervention. The remaining six participants that were not selected will function as controls. On average the investigators will aim to recruit a new batch every two weeks to start the initially more frequent intervention (from biweekly to monthly over six months) in stages. Therefore, all participants should have been randomised and started the trial within the first 3-4 months of the start of the trial. This phased randomisation/ recruitment to the trial is a due to limited resources and time restraints. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04679649
Study type Interventional
Source Royal United Hospitals Bath NHS Foundation Trust
Contact
Status Completed
Phase N/A
Start date October 6, 2021
Completion date July 30, 2022

See also
  Status Clinical Trial Phase
Completed NCT05031767 - Remote Monitoring of Axial Spondyloarthritis N/A
Completed NCT05162937 - to Evaluate the Preliminary Efficacy and Safety of GR1501 Injection in Patients With Active Axial Spondyloarthritis Phase 2
Completed NCT03622658 - Efficacy and Safety of Namilumab for Moderate-to-severe Axial Spondyloarthritis Phase 2
Completed NCT03248518 - Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases N/A
Terminated NCT02437162 - A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNFα Naive Participants With Active Radiographic Axial Spondyloarthritis Phase 3
Enrolling by invitation NCT06072859 - The Impact of Simulated Forest Immersion Therapy on Pain and Anxiety in Patients Axial Spondyloarthritis (axSpA) N/A
Completed NCT02552212 - Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS Phase 3
Active, not recruiting NCT01944163 - The IMPACT of a Referral Model for Axial Spondyloarthritis in Young Patients With Chronic Low Back Pain N/A
Active, not recruiting NCT02687620 - Does Immunogenicity Have an Influence on the Efficacy of Anti-TNF Therapy in Patients With AS: An Inception Cohort Study
Completed NCT00844805 - Infliximab for Treatment of Axial Spondyloarthritis (P05336 AM1) Phase 3
Terminated NCT02897115 - A Study Treating Participants With Early Axial Spondyloarthritis (axSpA) Taking an Intense Treatment Approach Versus Routine Treatment Phase 4
Completed NCT05019547 - The Turkish Version of the Inflammatory Arthritis Facilitators and Barriers to Physical Activity
Recruiting NCT03738956 - Safety and Efficacy of Tofacitinib in the Treatment of NSAID Refractory Axial Spondyloarthritis:A Clinical Trial Phase 2/Phase 3
Enrolling by invitation NCT02962479 - Is the Human Microbiome Altered in Patients With Axial Spondyloarthritis? N/A
Completed NCT04485078 - Investigation of Central Sensitization Frequency and Related Factors in Axial Spondyloarthritis Patients
Recruiting NCT05812157 - Optimizing Anti-IL17 Antibody Therapy by Associating Fiber Supplementation to Correct Treatment-aggravated Gut Dysbiosis in Axial Spondyloarthritis - RESPOND-IL17 N/A
Completed NCT03039088 - PREDICT-SpA - French Epidemiological Study of the Evaluation of the Impact of Fibromyalgia in the TNF Alpha Treatment Effect in Axial Spondyloarthritis in Both Anti-TNF naïve and - Experienced Patients
Completed NCT04368494 - Exercise Therapy in Patients With Axial Spondyloarthritis N/A
Completed NCT03270501 - Efficacy of Golimumab in Early Axial Spondyloarthritis in Relation to Gut Inflammation Phase 3
Completed NCT03043846 - Treat to Target Trial in Axial Spondylo Arthritis : The TICOSPA (Tight Control in Spondyloarthritis)